Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

Author(s): Collin M. Blakely, MD, PhD1,2; Anatoly Urisman, MD, PhD2,3; Matthew A. Gubens, MD, MS1,2; Claire K. Mulvey, MD1,2; Greg M. Allen, MD, PhD1,2; Stephen C. Shiboski, PhD4; Julia K. Rotow, MD5; Turja Chakrabarti, MD, MS1,2; D. Lucas Kerr, BS1,2; Jacqueline V. Aredo, MD, MS1; Bianca Bacaltos, MS2; Megan Gee, BS2; Lisa Tan, BS2; Kirk D. Jones, MD3; W. Patrick Devine, MD, PhD3,6; Robert C. Doebele, MD, PhD7; Dara L. Aisner, MD, PhD8; Tejas Patil, MD7; Erin L. Schenk, MD, PhD7; Trever G. Bivona, MD, PhD9; Jonathan W. Riess, MD, MS10; Melissa Coleman, MD2,11; Johannes R. Kratz, MD2,11; David M. Jablons, MD2,11
Source: https://doi.org/10.1200/JCO.24.00071
Original Article
Professional photo of Anjan J Patel, MD

Dr. Anjan Patel's Thoughts

Neoadjuvant Osimertinib did not have a significant impact on major pathologic response and there were no ypCR’s after a median of ~8 weeks of therapy. I do think this shows a measurable response, enough such that I would consider Osi in a patient with “borderline resectable” disease.

PURPOSE

To assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically resectable stage I-IIIA EGFR-mutated non–small cell lung cancer (NSCLC).

PATIENTS AND METHODS

This was a multi-institutional phase II trial of neoadjuvant osimertinib for patients with surgically resectable stage I-IIIA (American Joint Committee on Cancer [AJCC] V7) EGFR-mutated (L858R or exon 19 deletion) NSCLC (ClinicalTrials.gov identifier: NCT03433469). Patients received osimertinib 80 mg orally once daily for up to two 28-day cycles before surgical resection. The primary end point was major pathological response (MPR) rate. Secondary safety and efficacy end points were also assessed. Exploratory end points included pretreatment and post-treatment tumor mutation profiling.

RESULTS

A total of 27 patients were enrolled and treated with neoadjuvant osimertinib for a median 56 days before surgical resection. Twenty-four (89%) patients underwent subsequent surgery; three (11%) patients were converted to definitive chemoradiotherapy. The MPR rate was 14.8% (95% CI, 4.2 to 33.7). No pathological complete responses were observed. The ORR was 52%, and the median DFS was 40.9 months. One treatment-related serious adverse event (AE) occurred (3.7%). No patients were unable to undergo surgical resection or had surgery delayed because of an AE. The most common co-occurring tumor genomic alterations were in TP53 (42%) and RBM10 (21%).

CONCLUSION

Treatment with neoadjuvant osimertinib in surgically resectable (stage IA-IIIA, AJCC V7) EGFR-mutated NSCLC did not meet its primary end point for MPR rate. However, neoadjuvant osimertinib did not lead to unanticipated AEs, surgical delays, nor result in a significant unresectability rate.

Author Affiliations

1Department of Medicine, University of California, San Francisco, San Francisco, CA; 2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA; 3Department of Pathology, University of California, San Francisco, San Francisco, CA; 4Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA; 5Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA; 6Institute for Human Genetics, University of California, San Francisco, San Francisco, CA; 7Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; 8Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO; 9Chan Zuckerberg Biohub, San Francisco, CA; 10Department of Medicine, University of California Davis, Sacramento, CA; 11Department of Surgery, University of California, San Francisco, San Francisco, CA

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer

Confirmed objective response was 76% the median duration of response was 15.2 months and the median progression-free survival (PFS) was 14.4 months Of the patients with brain mets 47% had a confirmed intracranial objective response Zongertinib showed sustained efficacy in previously untreated patients with advanced or metastatic HER2-mutant Non–Small-Cell Lung Cancer (NSCLC) with mostly low-grade toxicity.

Read More »

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

45 patients with Non–Small-Cell Lung Cancer (NSCLC) who received the 600-mg dose, 36% had a partial response, the median progression-free survival (PFS) was 8.3 months, estimated 12-month overall survival was 59% 21 patients with metastatic pancreatic ductal adenocarcinoma 24% had a response, the median PFS was 3.0 months and the median overall survival was 10.3 months.

Read More »

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

The CHRYSALIS-2, the cohort C analysis of patients with atypical EGFR mutations showed meaningful and durable activity. Atypical mutations can be difficult to deal with as a clinician, and having concrete data on these (S768I, L861Q and G719ZX) mutations gives assurance that this doublet is active. Overall response rate (ORR) was 52% and median progression-free survival (PFS) was 11.1 months in refractory patients and 19.5 months in the treatment-naive population.

Read More »
Load More